The primary use of this medication is to help prevent the body's immune system from rejecting transplanted organs. It is applied across various therapeutic areas that involve the management of the immune response.

---

Supporting Organ Transplants and Managing Rejection

This application is used in clinical settings that involve allogeneic solid organ transplantation (e.g., kidney, liver, heart, lung). It is used for managing conditions linked to organ-specific functional stress, which can lead to organ damage and graft loss. The medication contributes to managing the overall impact associated with allogeneic solid organ transplantation by providing the assistance needed to maintain the new organ's function and functional stability.

---

Managing Severe Skin Inflammation and Complex Conditions

Панграф is used for managing conditions characterized by periods of heightened symptoms, including severe, refractory noninfectious uveitis and Graft-versus-host disease (GVHD). It is also applied in addressing severe localized skin inflammation in moderate to severe atopic dermatitis (eczema). This application supports the management of difficult episodes by helping to reduce symptom load and assisting with the improvement in skin lesion appearance.

Quick Fact: Relief for Severe Inflammation The medication is applied when symptoms are related to severe inflammatory or irritative states, assisting with maintaining functional stability.

Indications Summary: The medication is used to address symptoms related to immune response in solid organ transplantation; it is applied in addressing severe localized skin inflammation in moderate to severe atopic dermatitis; and it is applied for managing symptoms related to complex conditions like GVHD and specific forms of uveitis.

Eligibility Map: Who can and cannot use Панграф (Tacrolimus) — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

• Adult and pediatric recipients of allogeneic kidney, liver, and heart transplants.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to Tacrolimus or any component of its formulations.
• Patients allergic to Polyoxyl 60 Hydrogenated Castor Oil (HCO-60), an excipient found in the intravenous formulation.
• Female liver transplant patients using certain Extended-Release (ER) Tacrolimus products (e.g., ASTAGRAF XL), due to an increased mortality risk.

Age-related eligibility rules:

• Topical use is not recommended for children younger than 2 years of age.
• Geriatric patients may be treated without mandatory dose adjustment, but caution is advised due to the increased frequency of reduced organ function.

Condition-specific eligibility rules:

• Patients with severe hepatic impairment require a lower starting dose due to reduced drug clearance.
• Patients with renal impairment should be started at the lower end of the recommended oral dosing range.

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy: The drug may cause fetal harm; use is only permitted if the potential benefit justifies the risk.
• Lactation: Tacrolimus is excreted in human milk, and nursing/breastfeeding should be discontinued.

Eligibility-related restrictions:

• Switching between Immediate-Release (IR) and Extended-Release (ER) formulations is contraindicated unless conducted under strict medical supervision.

---

Eligibility classifications (high-level):

Classification	Examples of Affected Populations/Conditions
Contraindicated	Hypersensitivity, specific ER use in female liver recipients
Not Recommended	Topical use in children < 2 years or patients with skin barrier defects
Conditional Use/Caution	Severe hepatic impairment, renal impairment, pregnancy, lactation

Connection to the overall eligibility profile: Official government regulatory documents define who can and cannot use Tacrolimus by establishing formal contraindications (absolute prohibitions) and specific conditional restrictions related to age, physiological status, and organ function. These rules ensure the drug is reserved only for populations where use is officially established, while strictly excluding groups where the risk is formally documented as unacceptable.

The regulatory profile for Tacrolimus is categorized by distinct interaction types that affect drug concentration and toxicity risk. The most significant interactions are pharmacokinetic (PK), involving CYP3A4 enzyme and P-glycoprotein (P-gp) transporter. Co-administration with strong CYP3A4 inhibitors (such as certain antifungals like ketoconazole or antivirals like ritonavir) is officially stated to increase tacrolimus whole blood concentrations, necessitating careful regulatory restriction due to the risk of serious adverse reactions. Conversely, strong CYP3A4 inducers (like rifampin or phenytoin) are documented to decrease concentrations, increasing the official risk of graft rejection.

Pharmacodynamic (PD) interactions involve additive organ effects. Combining the drug with other nephrotoxic agents (e.g., aminoglycosides, cidofovir) is documented to increase the risk of nephrotoxicity. Similarly, combining with agents that increase potassium levels (e.g., ACE inhibitors) increases the risk of hyperkalemia.

Regulatory documents impose mandatory constraints. The co-administration of Ciclosporin is officially not recommended and requires a 12 to 24-hour delay in therapy initiation. Furthermore, official restrictions require avoiding the consumption of grapefruit products and the herbal product St. John’s Wort. For certain populations, such as patients with hepatic impairment, dose adjustments are noted in the label to manage altered pharmacokinetics and maintain target blood levels.

How Панграф Works

The mechanism of action of Панграф (Tacrolimus) is defined by its ability to precisely interrupt the signal required for T-lymphocytes to activate and multiply, resulting in the modulation of the T-cell mediated immune response.

---

Calcineurin Inhibition: The Molecular Switch Blockade

This cascade begins when Панграф enters the T-cell and binds to the intracellular receptor protein, FKBP12. This complex then strongly inhibits Calcineurin, a calcium-dependent phosphatase. This action modulates the activity of a molecular component that otherwise initiates the progression of the T-cell activation cascade.

---

Arresting the NFAT-Cytokine Signaling Cascade

By inhibiting Calcineurin, the drug prevents the dephosphorylation and activation of the transcription factor NFAT, keeping it sequestered in the cell's cytoplasm. This inhibition limits the synthesis and subsequent release of T-cell communication molecules, such as Interleukin-2 ( IL-2), which are integral to the propagation of the immune activation signal.

---

Physiological Suppression of T-Cell Proliferation

The resulting cellular deficiency of IL-2 limits the signaling required for T-cell proliferation and differentiation. This functional modulation results in a reduction of the destructive activity of T-lymphocytes, leading to a dampened T-cell mediated immunity.

The administration of Панграф (Tacrolimus) follows specific protocols designed to maintain precise systemic drug levels, which is crucial for its function as an immunosuppressant. The medication is available in several forms, including Immediate-Release (IR) capsules, Extended-Release (ER) capsules/tablets, a solution for Intravenous (IV) administration, and a topical ointment. The IV route is typically reserved for patients unable to tolerate oral intake, and the dose for IV infusion is lower than the oral dose.

Dosing is initiated based on the patient's body weight (in mg/kg), with the starting regimen differing based on the transplanted organ. The daily dose of IR capsules is typically divided and administered twice daily, while ER forms are taken once daily. The dose is not fixed long-term; instead, it is adjusted according to Therapeutic Drug Monitoring (TDM) of whole blood trough concentrations.

Proper administration involves attention to detail. Immediate-Release capsules are taken consistently with or without food at the same time every day to maintain reliable absorption. Conversely, Extended-Release forms are taken on an empty stomach (for example, one hour before or two hours after a meal). Furthermore, the use of grapefruit products and alcohol is avoided during use. Capsules are swallowed whole, and different Tacrolimus formulations are not interchangeable without specialist supervision. Pediatric patients often require higher mg/kg doses than adults, and patients with severe hepatic impairment may require a lower starting dose.

Research Evidence for Tacrolimus (Панграф)

This section provides an overview of the clinical research and evidence base for Tacrolimus, focusing on the types of studies conducted, the outcomes they measured, and areas where research remains incomplete or uncertain. This information is purely descriptive and should not be used for medical advice or treatment decisions.

---

Research Evidence for Mitigating Organ Rejection

The most extensive body of evidence for Tacrolimus was studied for its application in solid organ transplantation following the transplantation of organs such as the kidney, liver, heart, and lung. The research base for this purpose includes a large volume of available evidence from controlled, interventional trials.

Researchers examined the incidence and severity of acute rejection episodes and monitored endpoints related to long-term organ function and patient status. Stable drug levels were associated with patterns related to the consistency of long-term findings in the observed populations. The research protocol included close monitoring of drug levels during the evaluation of organ function.

The duration of follow-up in controlled trials was limited. Research is ongoing to fully understand the clinical impact of drug level variability over time and how it relates to late-stage outcomes.

---

Clinical Studies for Severe Atopic Dermatitis (Eczema)

The evidence for the topical ointment form of Tacrolimus, studied for moderate to severe atopic dermatitis (eczema), includes a large volume of research from multiple controlled trials.

These studies explored outcomes linked to inflammatory or irritative states, focusing on measuring changes in standardized severity scales, such as the Eczema Area and Severity Index (EASI). Longer-term studies examined maintenance strategies, where the research monitored symptom evolution during periods when the medication was applied to manage cycles of stability and flare-ups.

---

Research Gaps and Areas of Uncertainty

A key research limitation is the reliance on observational evidence for long-term outcomes (beyond five years) in transplantation. Secondly, the potential for systemic exposure from the long-term, widespread use of the topical ointment is still being monitored. Thirdly, research describes patterns related to drug levels, but the precise management and prediction of outcomes based on high or low intrapatient variability (IPV) in drug levels remains an area where ongoing research is needed.

Study results reflect the specific conditions under which they were conducted; research provides context but findings describe group patterns, not personal outcomes.

Common questions about Панграф (FAQ)

Q: What happens if I miss a dose of Панграф?

If you realize you have missed a dose, the official patient information generally advises that you take the dose as soon as you remember. However, if it is almost time for your next scheduled dose, the general guidance provided in patient information is to skip the missed dose and resume the regular schedule. Regulatory materials advise against taking two doses at the same time to compensate for a missed one.

---

Q: Are there any foods or drinks that should be avoided when taking Панграф?

Yes, official regulatory guidance states that grapefruit and grapefruit juice must be avoided because they can significantly increase the concentration of the medicine in your blood, raising the risk of toxicity. Alcohol must also be avoided. Additionally, if you are taking the Extended-Release form of the medicine, official instructions state it must be taken on an empty stomach (e.g., one hour before or two hours after a meal) for reliable absorption.

---

Q: Does alcohol consumption pose a risk while taking Панграф?

Official patient information advises that alcohol consumption must be avoided, as it can interact with the medicine and increase certain risks. It is also noted in the product label that the intravenous (IV) formulation of the medicine contains a high concentration of dehydrated alcohol.

---

Q: Does Панграф cause stomach upset or digestive issues?

According to the official product information, certain digestive issues are common. These include diarrhea and nausea (very common), as well as vomiting and constipation (common). Consistent with safety rules, any persistent or severe issues should be reported to the prescribing specialist.

---

Q: How often do I need blood tests while taking Панграф?

Official regulatory guidance requires mandatory and frequent monitoring of your blood levels, known as Therapeutic Drug Monitoring (TDM). This is necessary to keep the medicine's concentration in a precise target range. Monitoring is typically more frequent immediately after starting treatment or following a transplant, and continues regularly afterward.

---

Q: What are the long-term potential risks associated with using Панграф?

Because the medicine works by suppressing the immune system, long-term use is associated with officially recognized risks. These include officially recognized risks of increased susceptibility to serious infections, certain malignancies (cancers, particularly skin cancer), and potential organ toxicity, such as nephrotoxicity (kidney damage).

---

Q: Is long-term use of Панграф generally safe?

The medicine is indicated for long-term use as a necessary maintenance therapy to prevent organ rejection. The safety of its long-term use is dependent on continuous therapeutic drug monitoring and the careful management of officially recognized risks, including potential long-term toxicities.

---

Q: What is the typical duration of treatment with Панграф after a transplant?

The medicine is indicated for long-term use for the prevention of organ rejection. Regulatory documents imply that this therapy is generally required as a maintenance therapy for the life of the transplanted organ.

---

Q: What is the experience of switching from one immunosuppressant to Панграф?

Regulatory documents state this transition must be conducted under strict medical supervision. It typically requires a supervised delay (a washout period) of 12 to 24 hours between stopping the previous medicine (like Ciclosporin) and starting this one to minimize interaction risks.

---

Q: Can smoking affect the levels of Панграф in the blood?

Yes, smoking can potentially interfere with the drug's effectiveness. Components found in cigarette smoke are known as CYP3A4 inducers, which are officially documented to decrease the blood concentration of this medicine. Lower drug levels can increase the risk of the body rejecting the transplanted organ.

---

Q: Does Панграф affect mental clarity or mood?

Official safety information indicates the medicine can cause certain central nervous system (CNS) effects. These frequently reported side effects include headache and insomnia. More serious effects, such as disturbances in consciousness, are also documented as potential signs of neurotoxicity.

---

Q: How does Панграф differ from cyclosporine, in simple terms?

Both are powerful immunosuppressants known as Calcineurin Inhibitors that work similarly to reduce immune activity. However, clinical studies indicated that this medicine is generally considered more potent and has been associated with a lower rate of acute rejection compared to cyclosporine, though it may have a different pattern of side effects, such as a higher risk of tremor and diabetes.

---

Q: Can Панграф cause hair loss or skin problems?

Official safety data lists hair loss (alopecia) and various skin problems as possible side effects. The medicine also has an approved indication as a topical ointment for treating the skin condition atopic dermatitis (eczema).

---

Q: Is Панграф safe for children who have received a transplant?

Yes, the oral form of the medicine is officially indicated for the prevention of organ rejection in pediatric patients who have received a kidney, liver, or heart transplant. Official guidance notes that pediatric patients may need a higher dose of medicine per kilogram of body weight compared to adults.

---

Q: Is Панграф used for any autoimmune diseases besides transplant rejection prevention?

Yes, beyond transplantation, the medicine is officially used to manage an immune-mediated condition. The topical ointment formulation is indicated for the second-line treatment of moderate-to-severe atopic dermatitis (eczema) in patients who have not responded adequately to other topical treatments.

---

Q: Will Панграф cure the condition, or is it a long-term control medicine?

The medicine is used as a long-term control therapy, not a cure. Its primary function is to reduce or control the activity of the immune system to prevent the body from rejecting the transplanted organ.

---

Q: Can the effectiveness of Панграф be reduced by other herbal supplements?

Yes, official regulatory documents warn that the herbal product St. John’s Wort must be avoided. This supplement is a strong CYP3A4 inducer that can significantly decrease the blood levels of this medicine, which increases the critical risk of organ rejection.

---

Q: Is Панграф ever used as the sole immunosuppressant?

While this medicine is often used in combination with other drugs, regulatory documents mention that it may be possible to eventually withdraw some of the concomitant immunosuppressive therapy, leaving the patient on a dual-therapy regimen that includes this medicine.

---

Q: Can elderly patients take the same dose of Панграф as younger adults?

Official regulatory guidance states that mandatory dose adjustments based on age alone are not required for elderly patients. However, caution is advised because this population may more frequently experience reduced function of the kidneys, liver, or heart, which could affect how the drug is cleared from the body.

---

Q: Do studies suggest a difference in effectiveness between taking Панграф once or twice daily?

Clinical trials for the Extended-Release (once-daily) forms of the drug have demonstrated non-inferiority when compared to the Immediate-Release (twice-daily) forms. This means the studies found that both regimens were comparably effective in preventing acute rejection following kidney transplantation.

---

Q: What are the main benefits of using Панграф for its approved uses?

The main benefit described in regulatory and clinical documents is its role as a potent and selective immunosuppressant. It fundamentally limits the activation and multiplication of T-cells, which is critical for preventing the body's immune system from attacking and rejecting a transplanted organ. It also successfully suppresses the inflammatory symptoms of severe atopic dermatitis (eczema).

---

Q: How does being on Панграф affect my ability to travel?

While there are no specific travel restrictions, official guidance requires strict attention to the storage conditions of the medicine. The medicine must be kept at a controlled room temperature (typically 20 C to 25 C) and must be protected from both light and moisture to ensure its stability and effectiveness.

Storage and Disposal of Tacrolimus (Панграф)

The storage and disposal of Tacrolimus must strictly follow official regulatory guidelines to maintain its stability and prevent accidental exposure.

Item	Requirement (Official Regulatory Wording)
Storage Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Avoid freezing.
Protection	Keep the medicine out of the sight and reach of children. Must be protected from light and moisture.
Packaging	Store in the original container and keep it tightly closed.
Disposal	Dispose of unused or expired product according to local regulations. Do not flush or throw into wastewater.

Tacrolimus capsules in bulk containers may have a limited in-use shelf-life after opening, often requiring disposal after 12 months or by the expiration date, whichever comes first. Proper disposal via take-back programs ensures environmental safety.